Table 2.

Patient engagement and outcomes measures.

Outcomes, means			Assessment completeda (n=24)	No assessment completedb (n=24)	Overall total (n=96)	Overall P c
Physiological
	HbA1c
		Pre	8.71	8.82	8.79	.29
		Post	8.66	8.96	8.88
	LDL
		Pre	100.55	93.95	95.61	.06
		Post	100.71	109.29	107.27
	Body mass index
		Pre	40.41	39.71	39.87	.29
		Post	44.43	37.97	39.46
Utilization
	PCP visits
		Pre	5.46	5.44	5.45	<.001
		Post	1.75	2.42	2.25
	ED visits
		Pre	1.00	1.03	1.02	.001
		Post	0.46	0.64	0.59
Diabetes drug classes, PDC %
	PDC for biguanides (n=38)
		Pre	72	74	74	<.001
		Post	88	89	89
	PDC for thiazolidinediones (n=8)
		Pre	88	69	77	.004
		Post	96	91	93
	PDC for sulfonylureas (n=26)
		Pre	71	74	73	<.001
		Post	88	96	93
Cardiovascular drug classes, PDC %
	PDC for ACE inhibitors (n=45)
		Pre	90	85	85	.04
		Post	83	85	91
PDC for angiotensin II receptor
	Antagonists (ARB) (n=14)
		Pre	87	78	80	.02
		Post	96	92	93
	PDC for calcium channel blockers (n=18)
		Pre	92	85	87	.03
		Post	96	94	95
	PDC for beta blockers (n=30)
		Pre	86	73	75	<.001
		Post	94	90	91
PDC for 3-hydroxy-3-methyl-glutaryl CoA reductase
	Inhibitors (statins) (n=13)
		Pre	80	80	80	.02
		Post	99	91	94

^aPatients who completed at least one Web-based assessment

^bPatients who never logged in to complete an assessment

^cPaired t test P value, overall